CL2017002605A1 - Derivados de indol - Google Patents
Derivados de indolInfo
- Publication number
- CL2017002605A1 CL2017002605A1 CL2017002605A CL2017002605A CL2017002605A1 CL 2017002605 A1 CL2017002605 A1 CL 2017002605A1 CL 2017002605 A CL2017002605 A CL 2017002605A CL 2017002605 A CL2017002605 A CL 2017002605A CL 2017002605 A1 CL2017002605 A1 CL 2017002605A1
- Authority
- CL
- Chile
- Prior art keywords
- indole derivatives
- compounds
- well
- new
- prevention
- Prior art date
Links
- 229940054051 antipsychotic indole derivative Drugs 0.000 title 1
- 150000002475 indoles Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 101800002739 Melanin-concentrating hormone Proteins 0.000 abstract 1
- RHWPYOBZHMUSIP-UHFFFAOYSA-N N1C=CC=CC=N1.C1=CC=C2NC=CC2=C1 Chemical class N1C=CC=CC=N1.C1=CC=C2NC=CC2=C1 RHWPYOBZHMUSIP-UHFFFAOYSA-N 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- ORRDHOMWDPJSNL-UHFFFAOYSA-N melanin concentrating hormone Chemical compound N1C(=O)C(C(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)CNC(=O)C(C(C)C)NC(=O)C(CCSC)NC(=O)C(NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(NC(=O)C(N)CC(O)=O)C(C)O)CCSC)CSSCC(C(=O)NC(CC=2C3=CC=CC=C3NC=2)C(=O)NC(CCC(O)=O)C(=O)NC(C(C)C)C(O)=O)NC(=O)C2CCCN2C(=O)C(CCCNC(N)=N)NC(=O)C1CC1=CC=C(O)C=C1 ORRDHOMWDPJSNL-UHFFFAOYSA-N 0.000 abstract 1
- 102000047659 melanin-concentrating hormone Human genes 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Addiction (AREA)
- Anesthesiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
Abstract
<p>La presente invención se relaciona con nuevos derivados de diazepino-indol sustituido de la fórmula general (I), y con sales farmacéuticamente aceptable de los mismos, así como también con composiciones farmacéuticas que comprenden dichos compuestos, con nuevos intermedios de los mismos, así como también con el uso de dichos compuestos en tratamiento o prevención de trastornos asociados con actividad receptora de hormona que concentra melanina.</p>
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HUP1500169A HU230880B1 (hu) | 2015-04-15 | 2015-04-15 | Indol származékok |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017002605A1 true CL2017002605A1 (es) | 2018-03-16 |
Family
ID=89991787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017002605A CL2017002605A1 (es) | 2015-04-15 | 2017-10-13 | Derivados de indol |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US10329296B2 (es) |
| EP (1) | EP3286193B1 (es) |
| JP (1) | JP6783793B2 (es) |
| KR (1) | KR102591750B1 (es) |
| CN (1) | CN107466294B (es) |
| AR (1) | AR104261A1 (es) |
| AU (1) | AU2016248969B2 (es) |
| CA (1) | CA2982232C (es) |
| CL (1) | CL2017002605A1 (es) |
| CO (1) | CO2017011511A2 (es) |
| CU (1) | CU24451B1 (es) |
| CY (1) | CY1123185T1 (es) |
| DK (1) | DK3286193T3 (es) |
| EA (1) | EA034427B1 (es) |
| ES (1) | ES2804519T3 (es) |
| GE (1) | GEP20207067B (es) |
| HR (1) | HRP20201289T1 (es) |
| HU (2) | HU230880B1 (es) |
| IL (1) | IL254711B (es) |
| LT (1) | LT3286193T (es) |
| MX (1) | MX2017013201A (es) |
| MY (1) | MY189372A (es) |
| PE (1) | PE20180196A1 (es) |
| PH (1) | PH12017501736B1 (es) |
| PL (1) | PL3286193T3 (es) |
| PT (1) | PT3286193T (es) |
| RS (1) | RS60605B1 (es) |
| SA (1) | SA517390161B1 (es) |
| SG (1) | SG11201707772RA (es) |
| SI (1) | SI3286193T1 (es) |
| TW (1) | TWI703145B (es) |
| UA (1) | UA121046C2 (es) |
| UY (1) | UY36608A (es) |
| WO (1) | WO2016166684A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU231731B1 (hu) | 2022-06-17 | 2026-01-28 | Richter Gedeon Nyrt. | 4-[(5-klór-piridin-2-il)metoxi]-1-[3-(propán-2-il)-1H,2H,3H,4H,5H-[1,4]diazepino [1,7-a]indol-9-il]-1,2-dihidropiridin-2-on kristályos formái és ezek sói, valamint előállításuk és alkalmazásuk |
| HUP2200222A1 (hu) | 2022-06-17 | 2023-12-28 | Richter Gedeon Nyrt | MCHR1 antagonisták a Prader-Willi szindróma kezelésére |
| HUP2300374A1 (hu) | 2023-11-03 | 2025-05-28 | Richter Gedeon Nyrt | 18F és 11C radioaktívan jelzett MCHR1 PET ligandumok |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU193083B (en) * | 1984-02-22 | 1987-08-28 | Sandoz Ag | Process for preparing diazepinoindole derivatives further pharmaceutical compositions containing such compounds |
| NZ521389A (en) | 2000-03-14 | 2005-06-24 | Upjohn Co | 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds |
| CA2534428A1 (en) | 2003-08-13 | 2005-03-03 | Paul A. Tempest | Melanin concentrating hormone receptor antagonists |
| EP1916239A4 (en) | 2005-08-10 | 2009-10-21 | Banyu Pharma Co Ltd | PYRIDOLVERBINDUNG |
| US7851622B2 (en) | 2007-04-25 | 2010-12-14 | Bristol-Myers Squibb Company | Non-basic melanin concentrating hormone receptor-1 antagonists |
| US8198307B2 (en) | 2007-05-11 | 2012-06-12 | Korea Research Institute Of Chemical Technology | Imidazole derivatives having aryl piperidine substituent, method for preparation thereof and pharmaceutical compositions containing same |
| US20090011994A1 (en) | 2007-07-06 | 2009-01-08 | Bristol-Myers Squibb Company | Non-basic melanin concentrating hormone receptor-1 antagonists and methods |
| CA2727055C (en) | 2008-01-11 | 2016-12-20 | Albany Molecular Research, Inc. | (1-azinone) -substituted pyridoindoles as mch antagonists |
| SA110310332B1 (ar) | 2009-05-01 | 2013-12-10 | Astrazeneca Ab | مركبات ميثانون (3 استبدال -ازيتيدين -1-يل )(5- فينيل -1، 3، 4- أوكساديازول -2-يل ) |
| WO2010141539A1 (en) * | 2009-06-03 | 2010-12-09 | Glaxosmithkline Llc | Bis-pyridylpyridones as melanin-concentrating hormone receptor 1 antagonists |
| WO2011003005A1 (en) * | 2009-07-01 | 2011-01-06 | Albany Molecular Research, Inc. | Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine mch-1 antagonists, methods of making, and use thereof |
| WO2011127643A1 (en) | 2010-04-12 | 2011-10-20 | Merck Sharp & Dohme Corp. | Pyridone derivatives |
| WO2011130086A1 (en) * | 2010-04-12 | 2011-10-20 | Merck Sharp & Dohme Corp. | Pyridone derivatives |
| WO2012088124A2 (en) * | 2010-12-21 | 2012-06-28 | Albany Molecular Research, Inc. | Tetrahydro-azacarboline mch-1 antagonists, methods of making, and uses thereof |
| US8933079B2 (en) | 2012-03-07 | 2015-01-13 | Boehringer Ingelheim International Gmbh | Pyridone and pyridazinone derivatives as anti-obesity agents |
| WO2013149362A1 (en) | 2012-04-06 | 2013-10-10 | Glaxosmithkline Llc | 1-(dihydronaphthalenyl)pyridones as melanin-concentrating hormone receptor 1 antagonists |
| EP2892896B1 (en) | 2012-09-05 | 2016-06-29 | Bristol-Myers Squibb Company | Pyrrolone or pyrrolidinone melanin concentrating hormore receptor-1 antagonists |
| US20140163012A1 (en) * | 2012-12-11 | 2014-06-12 | Albany Molecular Research, Inc. | Pyrido-/azepino-benzofuran and pyrido-/azepino-benzothiophene mch-1 antagonists, methods of making, and use thereof |
-
2015
- 2015-04-15 HU HUP1500169A patent/HU230880B1/hu not_active IP Right Cessation
-
2016
- 2016-04-06 UY UY0001036608A patent/UY36608A/es active IP Right Grant
- 2016-04-12 TW TW105111384A patent/TWI703145B/zh active
- 2016-04-14 KR KR1020177031700A patent/KR102591750B1/ko active Active
- 2016-04-14 US US15/563,259 patent/US10329296B2/en active Active
- 2016-04-14 CA CA2982232A patent/CA2982232C/en active Active
- 2016-04-14 EA EA201792170A patent/EA034427B1/ru unknown
- 2016-04-14 WO PCT/IB2016/052110 patent/WO2016166684A1/en not_active Ceased
- 2016-04-14 PH PH1/2017/501736A patent/PH12017501736B1/en unknown
- 2016-04-14 AU AU2016248969A patent/AU2016248969B2/en active Active
- 2016-04-14 SG SG11201707772RA patent/SG11201707772RA/en unknown
- 2016-04-14 CU CU2017000128A patent/CU24451B1/es unknown
- 2016-04-14 HU HUE16718017A patent/HUE16718017T2/hu unknown
- 2016-04-14 SI SI201630891T patent/SI3286193T1/sl unknown
- 2016-04-14 MX MX2017013201A patent/MX2017013201A/es unknown
- 2016-04-14 DK DK16718017.3T patent/DK3286193T3/da active
- 2016-04-14 EP EP16718017.3A patent/EP3286193B1/en active Active
- 2016-04-14 AR ARP160101017A patent/AR104261A1/es active IP Right Grant
- 2016-04-14 PL PL16718017T patent/PL3286193T3/pl unknown
- 2016-04-14 PT PT167180173T patent/PT3286193T/pt unknown
- 2016-04-14 ES ES16718017T patent/ES2804519T3/es active Active
- 2016-04-14 LT LTEP16718017.3T patent/LT3286193T/lt unknown
- 2016-04-14 HR HRP20201289TT patent/HRP20201289T1/hr unknown
- 2016-04-14 RS RS20200889A patent/RS60605B1/sr unknown
- 2016-04-14 MY MYPI2017703515A patent/MY189372A/en unknown
- 2016-04-14 PE PE2017001613A patent/PE20180196A1/es unknown
- 2016-04-14 UA UAA201710857A patent/UA121046C2/uk unknown
- 2016-04-14 JP JP2017554052A patent/JP6783793B2/ja active Active
- 2016-04-14 GE GEAP201614624A patent/GEP20207067B/en unknown
- 2016-04-14 CN CN201680021685.5A patent/CN107466294B/zh active Active
-
2017
- 2017-09-26 IL IL254711A patent/IL254711B/en active IP Right Grant
- 2017-10-13 CL CL2017002605A patent/CL2017002605A1/es unknown
- 2017-10-15 SA SA517390161A patent/SA517390161B1/ar unknown
- 2017-11-09 CO CONC2017/0011511A patent/CO2017011511A2/es unknown
-
2020
- 2020-08-06 CY CY20201100739T patent/CY1123185T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020003532A (es) | Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrogenos y usos de los mismos. | |
| CY1123637T1 (el) | Αναστολεις μεθυλοτρανσφερασης αργινινης και χρησεις αυτων | |
| ECSP20070854A (es) | Compuestos heteroaril tetracíclicos | |
| NI201900039A (es) | Derivados de 6, 7, 8, 9-tetrahidro-3h-pirazolo[4, 3-f] isoquinolina útiles en el tratamiento del cáncer | |
| MX375639B (es) | Derivados de heterociclilos sustituidos como inhibidores de cdk | |
| CR20150472A (es) | USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd | |
| CL2018000697A1 (es) | Derivados de indol mono - o disustituidos como inhibidores de la replicación viral del dengue. | |
| CL2016001973A1 (es) | Derivados de nucleosido sustituidos con 4' -difluorometilo como inhibidores de la replicación de arn de la influenza. | |
| MX375978B (es) | Derivados de indol n-sustituidos como moduladores de los receptores de pge2. | |
| UY37742A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| MX2018011785A (es) | Derivados de indolina sustituidos como inhibidores de la replicacion viral del dengue. | |
| CO2018009559A2 (es) | Derivados de indol sustituidos como inhibidores de la replicación vírica del dengue | |
| CR20180496A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| ECSP17007208A (es) | Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble | |
| EA201591195A1 (ru) | Новые хинолоновые производные | |
| ECSP19062381A (es) | Moduladores del receptor de estrógeno | |
| CL2017001720A1 (es) | Nuevos derivados de bencimidazol como agentes antihistamínicos. | |
| CY1123185T1 (el) | Παραγωγα ινδολιου | |
| MX384987B (es) | Derivados del ácido acético azaindol y su uso como moduladores de receptor de prostaglandina d2. | |
| AR122456A2 (es) | Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos | |
| MX2017008497A (es) | Nuevos compuestos heterocíclicos y su uso tanto en medicina como en cosmética. | |
| EA201991734A1 (ru) | Модуляторы рецептора эстрогена | |
| UY35443A (es) | Derivados oxindol con un sustituyente oxetano y uso de los mismos para tratar enfermedades relacionadas con la vasopresina |